Abstract 3937
Background
Surgical resection is the only curative treatment for pancreatic cancer but is very invasive. It usually causes severe stress in patients and may cause pain and deterioration of quality of life (QOL). Patient-reported QOL data are essential for describing patient symptomatology and evaluating care to adequately manage symptoms. Here we evaluated changes in health-related QOL (HRQOL) and symptoms in pancreatic cancer patients after surgical intervention.
Methods
The institutional review board of our university approved this study (2012-1-403); patients provided written informed consent. A QOL questionnaire survey was administered preoperatively and at postoperative months 3, 6, and 12. We statistically evaluated the correlations between the Short Form 36 Health Survey version 2 (SF-36v2 Standard, Japanese), which measures HRQOL, and specific symptoms of hepatobiliary and pancreatic cancer, using data collected from 100 postoperative pancreatic cancer patients (subtotal stomach-preserving pancreatoduodenectomy (PD), 54 patients; distal pancreatectomy, 36 patients; total pancreatectomy (TP), 10 patients). Responses were analyzed by two-way ANOVA and Spearman’s correlation coefficient analysis; p < 0.05 was considered significant. All statistical analyses were performed using SPSS (ver. 21).
Results
QOL was lowest at 3 months postoperatively on many domains of the SF-36v2 and had gradually improved by 12 months postoperatively. At 3 months, physical functioning (PF) (p < 0.001) and role-physical (RP) (p < 0.01) were significantly reduced in PD and TP patients. Also, QOL deterioration on SF-36v2 domains was correlated with weight loss (PF, RP, vitality (VT), role-emotional (RE); p < 0.05), worse bowel control (PF, BP, VT, RE, mental health (MH); p < 0.01-0.05), indigestion (PF, RP, GH, VT, social functioning, RE, MH; p < 0.001-0.05), appetite loss (all domains; p < 0.001-0.01), fatigue (PF, RE, MH; p < 0.05), and inability to perform usual activities (all domains, p < 0.001).
Conclusions
QOL after pancreatectomy can be improved by nutrition management, treatment combinations for symptoms related to digestion and absorption, and treatment for subjective symptoms including fatigue.
Clinical trial identification
Editorial acknowledgement
Think Science KK.
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI Grant Number JP16K07140.
Disclosure
F. Motoi: Speaker Bureau / Expert testimony: Taiho Pharma, Mylan Japan, Daichi-Sankyo. M. Unno: Research grant / Funding (self): Taiho Pharma, Chugai; Research grant / Funding (institution): Taiho Pharma, Pfizer, Takeda, Chugai, Yakult, Asahi-Kasei. All other authors have declared no conflicts of interest.
Resources from the same session
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract